This follow-up report is submitted to the fda in accord with applicable regulations - and as indicated by terumo cardiovascular system in the initial report submitted to the fda on december 23, 2015.(b)(4).The product was not returned for evaluation, nor were the shipping records or documentation regarding the receipt of the product at the user facility.The device history records were reviewed in detail to trace the quantity of product produced.It was confirmed that the there was traceability for all of the product produced during this manufacturing work order; therefore, it is not likely that a case would have been packaged and shipped with two products missing.A definitive root cause could not be determined and the event was not confirmed.All available information has been placed on file in quality management for appropriate tracking, trending and follow up.
|